Wolfe Research upgraded Repligen (RGEN) to Outperform from Peer Perform with a $160 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen’s Strong Q1 Performance and Strategic Positioning Earns ‘Buy’ Rating from Analyst
- Repligen’s Strong Q1 Performance and Strategic Acquisition Justify Buy Rating
- Repligen reports Q1 adjusted EPS 39c, consensus 35c
- Repligen sees FY25 adjusted EPS $1.63-$1.72, consensus $1.71
- Is RGEN a Buy, Before Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue